Update on the Systemic Treatment of Biliary Tract Cancer in Canada

Biliary tract cancers (BTCs) are uncommon malignancies with poor outcomes, with many patients presenting with advanced, unresectable disease. Since publication of our 2023 practical guide, substantial advances have changed the systemic treatment landscape for BTC in Canada. Updated results from the TOPAZ-1 and KEYNOTE-966 trials have reinforced gemcitabine-cisplatin (GemCis) plus immunotherapy as the standard first-line treatment for unresectable or advanced BTC. Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) remains the standard second-line therapy for genetically unselected disease, while emerging evidence highlights additional approaches that may benefit selected patients. Comprehensive biomarker testing is increasingly important, with targeted therapies available through public reimbursement, clinical trials, or special access programs for patients with FGFR2 fusions or rearrangements, HER2 overexpression, IDH1 mutations, NTRK fusions, microsatellite instability/mismatch repair deficiency, and other actionable genomic alterations. Neoadjuvant therapy is an evolving approach for selected patients with resectable disease, with recent studies providing encouraging results, while adjuvant capecitabine remains the standard following curative-intent resection. Locoregional therapies, remain options for carefully selected patients, particularly those with liver-dominant disease. Despite these advances, access to therapies remains an important consideration in Canada, and multidisciplinary care and clinical trial participation remain essential to optimize outcomes.

Authors

Institutions

Publication Details

Journal
Current Oncology
Published
2026-11-19
DOI
https://doi.org/10.3390/curroncol33110719
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Update on the Systemic Treatment of Biliary Tract Cancer in Canada

Rachel Anne Goodwin, Ravi Ramjeesingh, Sarah Doucette
Current Oncology
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Update on the Systemic Treatment of Biliary Tract Cancer in Canada

Rachel Anne Goodwin, Ravi Ramjeesingh, Sarah Doucette
article en

Abstract

Biliary tract cancers (BTCs) are uncommon malignancies with poor outcomes, with many patients presenting with advanced, unresectable disease. Since publication of our 2023 practical guide, substantial advances have changed the systemic treatment landscape for BTC in Canada. Updated results from the TOPAZ-1 and KEYNOTE-966 trials have reinforced gemcitabine-cisplatin (GemCis) plus immunotherapy as the standard first-line treatment for unresectable or advanced BTC. Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) remains the standard second-line therapy for genetically unselected disease, while emerging evidence highlights additional approaches that may benefit selected patients. Comprehensive biomarker testing is increasingly important, with targeted therapies available through public reimbursement, clinical trials, or special access programs for patients with FGFR2 fusions or rearrangements, HER2 overexpression, IDH1 mutations, NTRK fusions, microsatellite instability/mismatch repair deficiency, and other actionable genomic alterations. Neoadjuvant therapy is an evolving approach for selected patients with resectable disease, with recent studies providing encouraging results, while adjuvant capecitabine remains the standard following curative-intent resection. Locoregional therapies, remain options for carefully selected patients, particularly those with liver-dominant disease. Despite these advances, access to therapies remains an important consideration in Canada, and multidisciplinary care and clinical trial participation remain essential to optimize outcomes.

Current OncologyVol. 33(11)
Dalhousie University (CA), University of Ottawa (CA), Ottawa Hospital (CA)
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon